Tristetraprolin (TTP) is a trans-acting factor that can regulate mRNA stability by binding to the cis-acting AU-rich element (ARE) in the 3Ј-untranslated region in mRNAs of certain transiently expressed genes. The best-studied target of TTP is tumor necrosis factor (TNF)-␣. By binding to ARE, TTP increases the degradation of TNF-␣ mRNA, thereby reducing the expression of TNF-␣. We examined the effects of cAMP analogs and the cAMP-elevating agents forskolin and ␤ 2 -agonists on lipopolysaccharide (LPS)-induced TTP mRNA and protein expression by quantitative real-time reverse transcriptase-polymerase chain reaction and Western blotting in activated macrophages. All of these agents caused a slight increase in LPSinduced expression of TTP mRNA. However, TTP protein levels were significantly reduced when the cells were treated with the combination of LPS and cAMP-elevating agent compared with LPS alone.
Post-transcriptional regulation of gene expression by cisacting elements and trans-acting factors has been an object of growing interest in recent years. One of the trans-acting factors regulating the stability of transiently expressed mRNAs is tristetraprolin (TTP), also known as Nup475, TIS11, G0S24, or Zfp36 (Blackshear, 2002) . The cis-acting element to which TTP binds resides in the AU-rich element (ARE) in the 3Ј-untranslated region of mRNAs of many inflammatory and other transiently expressed genes. The stability of an increasing number of transcripts has been shown to be regulated by TTP in studies with overexpression of TTP or by knockout (KO) or knockdown of TTP expression. Most studies have focused on the post-transcriptional regulation of tumor necrosis factor (TNF)-␣ mRNA. TTP can promote the deadenylation and decay of TNF-␣ mRNA by binding to the conserved ARE in the 3Ј-untranslated region of TNF-␣ mRNA (Lai et al., 1999; Lai and Blackshear, 2001) , thereby decreasing the amount of proinflammatory cytokine TNF-␣. TTP KO mice developed a complex inflammatory syndrome characterized by arthritis, autoimmunity, cachexia, and myeloid hyperplasia due to increased levels of TNF-␣ (Taylor et al., 1996; Carballo et al., 1998) .
Other suggested and/or partially confirmed targets of TTP include inflammatory modulators such as granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2, IL-3, IL-6, IL-12, macrophage inflammatory protein-2, macrophage inflammatory protein-3␣, inducible nitric oxide synthase, and cyclooxygenase-2 (Carballo et al., 2000; Stoecklin et al., 2000 Stoecklin et al., , 2001 Sawaoka et al., 2003; Linker et al., 2005; Ogilvie et al., 2005; Jalonen et al., 2006) . The most recent members in the group of mRNAs possibly regulated post-transcriptionally by TTP include suppressor of cytokine signaling 3 (SOCS3), transforming growth factor ␤1, and transcription factor E47 (Chang et al., 2007; Ehlting et al., 2007; Frasca et al., 2007) . However, studies using cells derived from TTP KO mice have not confirmed TTP as a sole regulator of mRNA stability of these genes. For instance, in the case of SOCS3, the results showed that in NIH 3T3 cells, down-regulation of TTP by small interfering RNA and TTP overexpression affected SOCS3 mRNA stability, but SOCS3 mRNA half-life was similar in cells from wild-type and TTP KO mice (Ehlting et al., 2007) .
In addition, there is increasing evidence that the p38 mitogen-activated protein kinase (MAPK) pathway is a crucial regulator of the expression, stability, and function of TTP (Mahtani et al., 2001; Brook et al., 2006; Hitti et al., 2006) . Phosphorylation of particular serine residues of TTP increases binding of 14-3-3 proteins, thereby excluding TTP from stress granules and inactivating TTP and increasing the stability of target mRNAs (Johnson et al., 2002; Chrestensen et al., 2004; Stoecklin et al., 2004) . In addition to stress granules, other sites where degradation of ARE-containing mRNAs has been shown to occur are the processing body (Franks and Lykke-Andersen, 2007; Stoecklin and Anderson, 2007) , the exosome (Chen et al., 2001) , and the proteasome (Laroia et al., 1999) . Micro-RNAs have also been reported to have a role in TTP-mediated mRNA degradation (Jing et al., 2005) . Whatever the site of mRNA degradation is, TTP protein has been proposed to be degraded by the proteasome Deleault et al., 2008) .
We have recently shown that ␤ 2 -agonists, cAMP analogs, and forskolin increase TTP mRNA and protein expression in resting cells, possibly by increasing the activation of transcription factor activator protein 2 (Jalonen et al., 2007) . In the present study, we found that TTP protein expression was differently regulated by cAMP-increasing compounds in cells exposed to LPS (which mimics the inflammatory situation) than in our earlier study in resting cells. Even though TTP mRNA amounts were increased, the TTP protein levels decreased when J774 macrophages were treated with a combination of LPS and cAMP-elevating agents. A possible mechanism of these effects is the increased degradation of TTP protein through the proteasome pathway because the inhibition of proteasome activity by proteasome inhibitors MG132 and lactacystin inhibited the decrease in TTP protein levels found with the combination of LPS and cAMP-elevating agents compared with treatment with LPS alone.
Materials and Methods
Materials. Reagents were purchased as follows: forskolin, MG132, and SB203580 from Tocris Cookson Inc. (Ellisville, MO), and ubiquitin aldehyde was from Boston Biochem (Cambridge, MA). All other reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Cell Culture. The murine J774 macrophages (European Collection of Cell Cultures, Porton Down, Wiltshire, UK) were maintained in an atmosphere of 5% carbon dioxide at 37°C in Dulbecco's modified Eagle's medium with UltraGlutamine 1 (Lonza Verviers SPRL, Verviers, Belgium) supplemented with 10% heat-inactivated fetal bovine serum (Lonza Verviers SPRL), penicillin (100 units/ml), streptomycin (100 g/ml), and amphotericin B (250 ng/ml) (Invitrogen, Paisley, UK). Cells were seeded on six-or 24-well plates and grown to confluence before the experiments. Tested compounds were added to the cell culture at the same time as LPS, unless otherwise stated.
Cell Viability Test. Cell viability was tested using the Cell Proliferation Kit II (Roche Diagnostics, Mannheim, Germany). Cells were incubated with LPS (1 ng/ml) or LPS (1 ng/ml) and forskolin (100 M) for 12 h before the addition of the sodium 3Ј-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate labeling reagent (final concentration, 0.3 mg/ml) and N-methyl dibenzopyrazine methyl sulfate (2.5 g/ml). Then, cells were incubated for 3 h, and the amount of formazan accumulated in the growth medium was assessed spectrophotometrically. No difference in cell viability between treated and untreated cells was detected. Triton X-treated cells were used as a positive control resulting in 97% reduction in cell viability.
RNA Extraction and Quantitative Real-Time Reverse Transcriptase-PCR. The protocol for RNA extraction and quantitative real-time reverse transcriptase (RT)-PCR has been described by Jalonen et al. (2005) . Primers and TaqMan 6-carboxyfluorescein (Fam)-TAMRA probes (Table 1) for TTP, TNF-␣, and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed using Primer Express Software (Applied Biosystems, Foster City, CA) and supplied by Metabion (Martinsried, Germany).
Western Blotting. The protocol for Western blotting has been described by Jalonen et al. (2005) . When preparing cell lysates for ubiquitin Western blotting, lysis buffer also contained ubiquitin aldehyde (20 g/ml) and MG132 (25 M) to prevent deubiquitinylation of the sample. The gels were loaded with 35 g of protein for TTP and actin Western blots and 240 g for ubiquitin Western blotting. Actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), the mouse TTP antibody (Cao et al., 2004) was kindly provided by Dr. Perry Blackshear (National Institute of Environmental Health Sciences, Research Triangle Park, NC), ubiquitin antibody was from Zymed Laboratories (South San Francisco, CA), p38 mitogen-activated protein kinase and phospho-p38 mitogen-activated protein kinase (Thr180/Tyr182) antibodies were from Cell Signaling Technology Inc. (Danvers, MA). The bound antibodies were detected using SuperSignal West Dura or Femto chemiluminescent substrate for horseradish peroxidase detection (Pierce Chemical, Cramlington, Northumberland, UK) and the FluorChem 8800 imaging system (Alpha Innotech, San Leandro, CA). Actin was used as a loading control, and it was detected from the same membrane as TTP after stripping the membrane. The chemiluminescent signals were measured with FluorChem software, version 3.1. Statistics. Results are expressed as the mean Ϯ S.E.M. The significance of differences was calculated by analysis of variance supported by Dunnett's adjusted significance levels. A difference between treatment groups was considered significant when p Ͻ 0.05.
Results
cAMP Analogs, Forskolin, and ␤ 2 -Agonists Decreased LPS-Induced TTP Protein Expression in J774 Macrophages. In resting cells, low levels of TTP protein were detected. LPS (1 ng/ml) induced transient expression of TTP protein, which enhanced rapidly, remained relatively constant for 4 to 9 h, and declined thereafter (data not shown). After incubation with LPS (1 ng/ml) for 9 h, TTP protein amount was increased 5-fold in J774 macrophages compared with resting cells (Fig. 1A) . cAMP analogs N 6 ,2Ј-O-dibutyryladenosine 3Ј,5Ј-cyclic monophosphate sodium salt (db-cAMP; 1 mM) and 8-bromoadenosine 3Ј,5Ј-cyclic monophosphate sodium salt (8-Br-cAMP; 1 mM) decreased LPS-induced TTP protein expression by 40% (Fig. 1A) . At lower concentrations (0.1 mM), db-cAMP was less efficient than 8-Br-cAMP in decreasing TTP protein levels. Likewise, forskolin (an activator of adenylate cyclase; 100 M) decreased LPS-induced TTP protein levels by 45% when measured after 9 h of incubation (Fig. 1B) . In addition to the cAMP analogs and forskolin, ␤ 2 -agonists salbutamol and terbutaline (0.3 and 1 M) decreased LPS-induced TTP protein levels by 41 to 50% when measured after 9-h incubation (Fig. 1C) .
cAMP Analogs, Forskolin, and Salbutamol Increased LPS-Induced TTP mRNA Levels in J774 Macrophages. Low levels of TTP mRNA were found in unstimulated cells, and that was significantly increased when LPS (1 ng/ml) was added into the culture. J774 macrophages were incubated with LPS (1 ng/ml) and 8-Br-cAMP or db-cAMP (0.1 or 1 mM) for 1 h ( Fig. 2A) . 8-Br-cAMP (0.1 and 1 mM) increased TTP mRNA levels by 49 and 79%, respectively, compared with cells treated with LPS only. db-cAMP (0.1 and 1 mM) had a similar effect and enhanced TTP mRNA levels by 37 and 93% compared with LPS-treated cells. When the cells were incubated with LPS (1 ng/ml) in combination with forskolin (100 M), TTP mRNA levels were higher than when treated with LPS (1 ng/ml) alone (Fig. 2B) . The difference between the treatments was statistically significant after 1-and 2-h incubation. A slight increase in TTP mRNA levels was also observed when the cells were treated with LPS (1 ng/ml) and increasing concentrations (0.1-3 M) of salbutamol for 1 h Forskolin Did Not Affect TTP mRNA Half-Life in LPS-Treated J774 Macrophages. To find out the reasons for the differences between mRNA and protein expression, we first examined the degradation rate of TTP mRNA by actinomycin D assay (Fig. 3 ). Cells were treated with LPS (1 ng/ml) in the presence or absence of forskolin (100 M) for 1 h; thereafter, actinomycin D (0.5 g/ml) was added to the culture to inhibit transcription. Total RNA was extracted 2, 4, and 5 h after addition of actinomycin D, and the TTP mRNA levels were measured. Forskolin did not alter the TTP mRNA degradation rate, and the half-life of TTP mRNA with both treatments was approximately 4.5 h.
Forskolin, cAMP Analogs, and ␤ 2 -Agonists Decreased LPS-Induced TTP Protein Expression in a Time-Dependent Manner. Because forskolin had no effect on TTP mRNA half-life, we examined its effects on TTP protein expression after different incubation times (Fig. 4A ). Macrophages were incubated with LPS (1 ng/ml) with or without forskolin (100 M), and proteins were extracted after 4, 6, 9, and 12 h of culture. With both treatments, TTP protein levels were almost equal when measured after 4-h incubation. After 6-h incubation, TTP protein levels were 10% lower in forskolintreated cells. After 9-and 12-h incubations, LPS-induced TTP protein levels were 51 and 57% lower in forskolintreated cells, respectively. In addition, TTP mRNA levels were measured at the same time points (Fig. 4B) . As expected, after 4-h incubation, TTP mRNA levels were higher in forskolin-treated cells. In contrast, after 6-, 9-, and 12-h incubation, the TTP mRNA levels in LPS ϩ forskolin-treated cells were similar to those in cells treated with LPS only.
Thereafter, we investigated the effects of cAMP analogs and the ␤ 2 -agonist on TTP protein levels (Fig. 5) . The cells were treated with LPS (1 ng/ml) with or without the cAMP analogs or ␤ 2 -agonist. Proteins were extracted after 4-and 9-h incubation, and TTP protein was detected by Western blot. After 4-h incubation, LPS-induced TTP protein levels were approximately similar in control cells and in cells Fig. 2 . Effects of cAMP analogs, forskolin, and salbutamol on LPS-induced TTP mRNA expression in J774 macrophages. A, LPS (1 ng/ml) and indicated concentrations of 8-Br-cAMP or dbcAMP were used to stimulate macrophages for 1 h, after which total RNA was extracted. Quantitative RT-PCR was used to measure TTP mRNA, and the values were normalized to GAPDH mRNA. The mean of TTP mRNA levels in the LPS-treated samples was set at 100, and the other values were related to that. Values are mean Ϯ S.E.M. (n ϭ 3) . ‫,ءء‬ p Ͻ 0.01 and ‫,ء‬ p Ͻ 0.05 when compared with the LPS-treated samples. B, cells were stimulated with LPS (1 ng/ml) in combination with forskolin (100 M). Total RNA was extracted at the time points indicated. Quantitative RT-PCR was used to measure TTP mRNA, and the values were normalized to GAPDH mRNA. The mean of TTP mRNA levels in the LPS-treated samples at the 1-h time point was set at 100, and the other values were related to that. Values are mean Ϯ S.E.M. (n ϭ 3) . ‫,ءء‬ p Ͻ 0.01 when compared with the LPStreated samples in each time point. C, LPS (1 ng/ml) and indicated concentrations of salbutamol were used to stimulate macrophages for 1 h, after which total RNA was extracted. Quantitative RT-PCR was used to measure TTP mRNA, and the values were normalized to GAPDH mRNA. The TTP mRNA level in the LPS-treated samples was set at 100, and the other values were related to that. Values are mean Ϯ S.E.M. (n ϭ 3). ‫,ءء‬ p Ͻ 0.01 and ‫,ء‬ p Ͻ 0.05 when compared with the LPS-treated samples. jpet.aspetjournals.org treated with 8-Br-cAMP, db-cAMP, or salbutamol. After 9-h incubation, all of the three compounds significantly decreased the level of TTP protein expression. The cAMP analogs 8-Br-cAMP and db-cAMP decreased TTP protein levels after 9-h incubation by 52 and 40%, respectively. Likewise, salbutamol decreased the amount of TTP protein by 41%. In conclusion, the results suggest that cAMP analogs and cAMP-elevating agents increase the rate of TTP protein degradation.
Proteasome Inhibitors Abolished Differences between TTP Protein Levels Extracted from LPS-and LPS ؉ Forskolin-Treated J774 Macrophages. We used two inhibitors of proteasome, lactacystin and MG132, to investigate whether the proteasome-mediated degradation of TTP protein is increased with forskolin in LPS-treated cells. First, we wanted to confirm that lactacystin, an inhibitor of 20S and 26S proteasomes, has a functional effect as a proteasome inhibitor in the cell culture conditions used. When protein degradation through the proteasome is inhibited, ubiquitinated proteins accumulate in the cells. Therefore, we examined the effects of lactacystin on the levels of ubiquitinated cellular proteins (Fig. 6A) . The cells were first treated with or without LPS (10 ng/ml) for 8 h, and then lactacystin (10 M) was added to inhibit the activity of proteasome. Total proteins were extracted as described under Materials and Methods after 16-h incubation with lactacystin. Ubiquitinated proteins were detected with ubiquitin antibody. Addition of lactacystin to untreated cells increased the amount of ubiquitinated proteins as can be seen in Fig. 6A , lanes 1 and 2. An even greater increase of ubiquitinated proteins in cells by lactacystin could be seen in samples extracted from LPStreated cells (see Fig. 6A, lanes 3 and 4) . J774 macrophages were incubated for 5 h with LPS (1 ng/ml) in the presence or absence of forskolin (100 M) before lactacystin (20 M) was added into the culture (Fig. 6B ). Incubations were continued for 4 h, after which proteins were extracted and detected by Western blot. Addition of lactacystin increased LPS-induced TTP protein levels by 68%, suggesting that the degradation of TTP protein was decreased during inhibition of the proteasome. In the absence of lactacystin, forskolin reduced the amount of LPS-induced TTP protein by 45%. When lactacystin was added to the culture, forskolin had no effect on TTP protein levels.
Another inhibitor of proteasome, MG132, was used to assess the effect of forskolin on TTP protein degradation in a similar experiment (Fig. 6C) . The cells were first incubated with LPS (1 ng/ml) with or without forskolin (100 M) for 6 h before MG132 (10 M) was added. Incubation was continued for another 6 h. After protein extraction, TTP and actin proteins were detected by Western blot. MG132 increased TTP protein levels of LPS-treated samples more than 10-fold, indicating that without the inhibitor of proteasome large amounts of TTP protein are degraded by the proteasome. In the absence of MG132, forskolin decreased LPS-induced protein levels by 55%. In the presence of MG132, forskolin did not alter TTP protein levels.
LPS and LPS ؉ Forskolin Activated MAPK p38 at 30 min but Not at 9 h. Activation of p38 by phosphorylation was studied by Western blot (Fig. 7A) . J774 macrophages were treated with LPS (1 ng/ml) with or without forskolin (100 M) for 30 min or 9 h, after which proteins were extracted, and phosphorylated and total p38 were detected by Western blot. Thirty-minute incubation with LPS or LPS ϩ forskolin increased the amount of phosphorylated p38 3 or 4-fold, respectively, compared with control. After 9-h incubation, phospho-p38 levels were very low, and there were no differences between the treatments.
The p38 pathway is one of the regulators of TTP transcription. To find out whether the inhibition of p38 activation affects the mRNA levels of TTP, we treated the J774 macrophages with different combinations of LPS (1 ng/ml), forskolin (100 M), and p38 inhibitor SB203580 (1 M) (Fig. 7B) . Total RNA was extracted after 1-h incubation, and TTP mRNA was measured by quantitative PCR. Both LPS-induced and LPS ϩ forskolin-induced TTP mRNA levels were inhibited by the p38 inhibitor SB203580 by 51 to 53%, indicating that p38 regulates TTP mRNA expression both in LPS and LPS ϩ forskolin-treated cells.
Forskolin Decreased TNF-␣ mRNA Decay in LPSTreated J774 Macrophages. Because TNF-␣ mRNA is a well known target of TTP, and its decay is increased by TTP, we measured TNF-␣ mRNA decay by actinomycin D assay at a time point when the forskolin-induced reduction in TTP protein amount was most significant (Fig. 8) . Macrophages were treated with LPS (1 ng/ml) in the presence or absence of forskolin (100 M) for 9 h; thereafter, actinomycin D was added. Total RNA was extracted at 60 and 90 min after addition of actinomycin D, and TTP mRNA levels were measured. As seen in Fig. 8 , TNF-␣ mRNA decay was slower in LPS ϩ forskolin-treated cells that in cells exposed to LPS only.
Discussion
The principal finding in the present study was that cAMP analogs, forskolin, and ␤ 2 -agonists decreased LPS-induced TTP protein expression by increasing the rate of TTP degradation via proteasome. The role of p38 in the regulation of TTP expression was also studied, indicating a role for p38 in the regulation of TTP mRNA expression at early time points. The results suggest a novel mechanism by which mediators or drugs that increase intracellular cAMP concentrations may participate in the up-regulation of the expression of inflammatory genes.
Experiments on TTP KO mice and cells derived from them have shown that TTP is a physiological regulator to reduce mRNA stability and, hence, the expression of two important proinflammatory cytokines, TNF-␣ and GM-CSF (Taylor et al., 1996; Carballo et al., 1998 Carballo et al., , 2000 . Due to increased levels of TNF-␣ and GM-CSF, the TTP KO mice suffer from arthritis-like symptoms, autoimmunity, and myeloid hyperplasia (Taylor et al., 1996; Phillips et al., 2004) . In this study, we showed that forskolin reduced LPS-induced TTP protein levels significantly after 9-h incubation (i.e., by approximately 50% based on the Western blot results). Forskolin also reduced TNF-␣ mRNA decay, suggesting that the forskolininduced changes in TTP levels may be functionally significant. In our earlier study, down-regulation of TTP expression by small interfering RNA by approximately 50% resulted in increased release of TNF-␣ and some other cytokines from activated macrophages (Jalonen et al., 2006) . That result further supports that down-regulation of TTP expression by the degree found in the present study may have significant effects in macrophages.
In addition to arthritis, recent studies suggest that TTP has a potential role in cancer and in obesity-related metabolic complications (Bouchard et al., 2007; Carrick and Blackshear, 2007) . The possibility to regulate TTP expression to treat these conditions with future drugs requires intensive study of the regulation TTP expression and the effects of TTP over-and underexpression. Only little is known about the pharmacological regulation of TTP expression. Dexamethasone has been shown to increase TTP mRNA and protein levels in resting human A549 lung epithelial cells and in rat lung tissue (Smoak and Cidlowski, 2006) . On the other hand, dexamethasone reduced LPS-induced TTP expression in J774 macrophages (Jalonen et al., 2005) . Interferons have been reported to up-regulate TTP expression, which in turn results in down-regulation of several proinflammatory genes (Sauer et al., 2006) . Cinnamon extract and cinnamon polyphenols have been shown to increase both the protein and mRNA levels of TTP in mouse adipocytes (Cao et al., 2007b) . In addition, green tea, which is also associated with antiinflammatory effects, increased the levels of TTP mRNA in rat liver and skeletal muscle (Cao et al., 2007a) .
We recently reported that the expression of TTP mRNA and protein could be induced by ␤ 2 -agonists, cAMP analogs, and forskolin in resting macrophages, and that was probably mediated by increased activator protein 2 activation (Jalonen et al., 2007) . Here, we have shown that when these compounds were given in combination with LPS, which mimics the inflammatory situation, TTP protein levels were significantly decreased. The decrease in TTP protein amounts could be prevented by treating the cells with proteasome inhibitors MG132 and lactacystin. The observed decrease in TTP protein levels in cells treated with LPS in combination with cAMP-elevating agents compared with treatment with LPS alone may be caused by enhanced activity of the proteasome activated by cAMP. This assumption is supported by earlier findings that phosphorylation of an ATPase in the 19S cap of the mammalian proteasome, Rpt6, by cAMP-dependent protein kinase A enhances proteasome activity (Zhang et al., 2007) . cAMP seems to regulate the expression of TTP differently in resting cells and in cells exposed to inflammatory stimulus. It is interesting to note that very similar results have been reported with glucocorticoid dexamethasone. Dexamethasone, in combination with LPS, decreased TTP expression in mouse macrophages (Jalonen et al., 2005) , but in resting human A549 lung epithelial cells and in rat lung tissues (in the absence of inflammatory stimuli), dexamethasone increased TTP mRNA and protein levels (Smoak and Cidlowski, 2006) .
In contrast to TTP mRNA, which is transiently expressed, TTP protein has been regarded to be fairly stable, and the stability is regulated by p38 MAPK and its downstream target, MAPK-activated protein kinase 2, and extracellular signal-regulated kinase (Cao et al., 2004; Brook et al., 2006; Hitti et al., 2006; Deleault et al., 2008) . It has been suggested that dephosphorylation of TTP directs TTP to the proteasome by an unknown mechanism to be rapidly degraded Deleault et al., 2008) . TTP protein sequence contains three PEST domains (proline, glutamic acid, serine, and threonine) that target proteins for degradation by proteasome, but studies with mutated domains have not yet shown the functional activity of these domains (Rigby et al., 2005) . Here, we provide further evidence that TTP protein expression is down-regulated by degradation through proteasome by showing that two proteasome inhibitors (lactacystin and MG132) enhanced TTP protein levels. Phosphorylation of p38 was also examined at 30 min and 9 h to gain mechanistic information on the regulation of TTP expression. The results suggest that at early time points, when p38 is activated by phosphorylation, it activates TTP transcription. At later time points, when p38 has been inactivated by phosphatases, the phosphorylation status of TTP also may decrease, enabling the degradation of TTP protein. We suggest that the degradation through the proteasome is an inducible mechanism to withdraw TTP from the cells and serves as a regulatory mechanism that enhances the inflammatory reaction by limiting the duration of TTP expression. Although the expression of TTP is regulated in a similar manner in resting mouse and human macrophages by cAMP-elevating agents (Jalonen et al., 2007) , the results described in the present study require confirmation in human macrophages. Many factors increase intracellular cAMP levels through G-proteincoupled receptors in cell membrane, indicating that several Fig. 6 . Effects of proteasome inhibitors on TTP protein expression in J774 macrophages. A, cells were incubated with or without LPS (10 ng/ml) for 8 h before the addition of lactacystin (10 M). Proteins were extracted 16 h after the addition of lactacystin, and protein ubiquitination was analyzed by Western blot. The blot is a representative of three with similar results. B, J774 macrophages were treated with LPS (1 ng/ml) with or without forskolin (100 M) for 5 h, and then lactacystin (20 M) was added. Incubation was continued for 4 h, after which proteins were extracted. TTP and actin proteins were measured by Western blot. The TTP protein level in the LPS-treated samples was set at 100, and the other values were related to that. The blot is a representative of three with similar results. Values are mean Ϯ S.E.M. (n ϭ 3). ‫,ءء‬ p Ͻ 0.01 and N.S. (ns) when compared with the LPS-and LPS ϩ lactacystin-treated samples. C, J774 macrophages were incubated with LPS (1 ng/ml) with or without forskolin (100 M) for 6 h before MG132 (10 M) was added, and incubation was continued for another 6 h. Proteins were extracted, and TTP and actin protein were detected by Western blot. The TTP protein level in the LPS-treated samples was set at 100, and the other values were related to that. other factors than those tested in the present study may also increase TTP protein degradation in a similar manner.
The data in the present study suggest that activation of cAMP-mediated mechanisms by cAMP analogs, forskolin, and ␤ 2 -agonists decreases LPS-induced TTP protein expression in macrophages possibly through the activation of proteasome. The results described here provide a mechanism by which the expression of TTP can be turned off at sites of inflammation. ␤ 2 -Agonists have been reported to have antiinflammatory effects in various in vitro conditions but these actions do not clearly translate into the in vivo situation, e.g., in inflamed lung tissue in patients with asthma (Sitkauskiene and Sakalauskas, 2005) . The mechanism described in the present study and in our earlier study (Jalonen et al., 2007) could, at least partly, explain the discrepancy between these in vitro and in vivo findings. In vivo, in situations with an ongoing inflammation, the expression of TTP can be down-regulated by ␤ 2 -agonists. In the absence of an LPS-like inflammatory stimulus, these agents could increase the amount of TTP. Actually, the increased TTP degradation may be involved in the enhancement of asthmatic inflammation sometimes seen in asthma patients treated with ␤ 2 -agonists only without concomitant inhaled anti-inflammatory steroids. Our results suggest that compounds that increase or mimic cAMP decrease LPS-induced TTP protein expression, possibly by directing TTP for degradation through the proteasome, which is likely to enhance the expression of factors regulated by TTP. Fig. 7 . Effects of LPS and forskolin on p38 activation and the suppressive effect of p38 inhibitor SB203580 on TTP mRNA expression in J774 macrophages. A, cells were treated with LPS (1 ng/ml) and forskolin (100 M) for 30 min or 9 h. Proteins were extracted, and phospho-p38 (pp38), total p38, and actin proteins were measured by Western blot. The phospho-p38 protein level in the LPS-treated samples was set at 100, and the other values were related to that. The blot is a representative of four with similar results. Values are mean Ϯ S.E.M. (n ϭ 4). ‫,ءء‬ p Ͻ 0.01 when compared with the control samples at the 30-min time point. B, cells were incubated with LPS (1 ng/ml), forskolin (100 M), and p38 inhibitor SB203580 (1 M) as indicated for 1 h, after which total RNA was extracted. Quantitative RT-PCR was used to measure TTP mRNA, and the values were normalized to GAPDH mRNA. The mean of TTP mRNA levels in the LPS-treated samples was set at 100, and the other values were related to that. Values are mean Ϯ S.E.M. (n ϭ 4). ‫,ءء‬ p Ͻ 0.01 when compared with the LPS-treated or LPS ϩ forskolin-treated sample. 
